Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single ascending dose study of intravenous ALX 0651 in healthy male volunteers
NL-OMON35929Phase 1Active, not recruiting
- Sponsor
- Ablynx
- Start
- Jun 2011
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of ALX-0651 in peripheral blood progenitor cell mobilization, sponsored by Ablynx. Primary endpoints: Safety and tolerability, Pharmacokinetics and 2 more. Started Jun 2011; status: active, not recruiting.
02
Drugs
ALX-0651
03
Conditions
peripheral blood progenitor cell mobilization
Beyond the preview
Go deeper on NL-OMON35929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35929.